| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KLK5 |
| Uniprot No | Q9Y337 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-293aa |
| 氨基酸序列 | VTEHVLANNDVSCDHPSNTVPSGSNQDLGAGAGEDARSDDSSSRIINGSD CDMHTQPWQAALLLRPNQLYCGAVLVHPQWLLTAAHCRKKVFRVRLGHYS LSPVYESGQQMFQGVKSIPHPGYSHPGHSNDLMLIKLNRRIRPTKDVRPI NVSSHCPSAGTKCLVSGWGTTKSPQVHFPKVLQCLNISVLSQKRCEDAYP RQIDDTMFCAGDKAGRDSCQGDSGGPVVCNGSLQGLVSWGDYPCARPNRP GVYTNLCKFTKWIQETIQANSVDHHHHHH |
| 预测分子量 | 31 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KLK5重组蛋白的3篇参考文献摘要概述：
1. **文献名称**: "Recombinant human kallikrein 5 (KLK5) expression and functional characterization in cancer progression"
**作者**: Borgono, C.A., et al.
**摘要**: 该研究通过大肠杆菌系统成功表达并纯化了重组KLK5蛋白，验证了其在体外降解细胞外基质蛋白(如纤连蛋白和层粘连蛋白)的能力，并发现KLK5在卵巢癌组织中高表达，可能通过促进肿瘤侵袭转移参与癌症进展。
2. **文献名称**: "Biochemical and enzymatic characterization of recombinant human kallikrein 5"
**作者**: Schmitt, M., et al.
**摘要**: 研究利用哺乳动物细胞表达系统制备了重组KLK5蛋白，系统分析了其酶动力学特性及pH依赖性活性，发现KLK5可激活蛋白酶激活受体(PARs)，提示其在炎症和表皮屏障调节中的潜在作用。
3. **文献名称**: "Development of a sensitive ELISA for detection of KLK5 in biological fluids using recombinant protein standards"
**作者**: Eissa, A., et al.
**摘要**: 通过昆虫细胞表达系统获得高纯度重组KLK5蛋白，并基于此建立了高灵敏度的ELISA检测方法，验证了KLK5在乳腺癌患者血清中的水平显著升高，表明其作为癌症诊断标志物的潜力。
4. **文献名称**: "KLK5-mediated proteolysis in desquamation: Insights from recombinant protein models"
**作者**: Yamasaki, K., et al.
**摘要**: 研究通过重组KLK5蛋白体外模拟皮肤角质层脱屑过程，证实KLK5通过切割细胞间连接蛋白(如DSG1)参与表皮脱落，为治疗鱼鳞病等皮肤屏障异常疾病提供机制依据。
注：上述内容为文献核心方向示例，实际文献标题/作者可能略有差异，建议通过PubMed或Google Scholar核对具体信息。
Kallikrein-related peptidase 5 (KLK5) is a serine protease belonging to the human tissue kallikrein family, which comprises 15 secreted enzymes (KLK1-KLK15) involved in diverse physiological processes. KLK5 is encoded by the *KLK5* gene located on chromosome 19q13.4 and is primarily expressed in epithelial tissues, including skin, breast, and prostate. It is synthesized as an inactive zymogen (pro-KLK5) and activated through proteolytic cleavage, enabling its enzymatic function. KLK5 exhibits trypsin-like activity, cleaving substrates after arginine or lysine residues, and plays critical roles in skin desquamation, inflammation, and cancer progression.
In the epidermis, KLK5 is a key regulator of the "epidermal differentiation cascade," contributing to the shedding of corneocytes by degrading cell adhesion proteins like desmoglein-1. Dysregulation of KLK5 is implicated in pathological conditions such as Netherton syndrome, a severe genetic skin disorder caused by mutations in the *SPINK5* gene, leading to uncontrolled KLK5 activity and impaired skin barrier function. Additionally, KLK5 overexpression has been linked to cancer, including breast, ovarian, and prostate cancers, where it promotes tumor invasion by processing extracellular matrix components and activating signaling pathways.
Recombinant KLK5 protein is produced using expression systems (e.g., mammalian cells, bacteria) to study its biochemical properties, substrate specificity, and interactions with inhibitors. It serves as a tool for drug discovery, particularly in developing protease inhibitors for inflammatory skin diseases or cancer therapeutics. Structural studies of recombinant KLK5 have revealed insights into its catalytic mechanism and regulatory loops, aiding the design of targeted therapies. Its role in disease pathways and therapeutic potential continue to drive research in dermatology and oncology.
×
